Adverum Biotechnologies will change how patients receive steroids to manage inflammation in the third and fourth cohorts of its phase 1 OPTIC trial, the company announced in a press release.
The multicenter, open-label, dose-escalation OPTIC trial is assessing the safety and tolerability of a single injection of ADVM-022, a gene therapy candidate that uses a propriety vector capsid to deliver sustained therapeutic levels of aflibercept in patients with wet age-related macular degeneration.
In previous cohorts, patients received prophylactic oral steroids; however, in the third cohort, which
Uncategorized